What are the efficacy ratings of Cosentyx compared to other psoriasis treatments?
Cosentyx (secukinumab) is a fully human monoclonal antibody that has been shown to be effective in treating plaque psoriasis [1]. In clinical trials, Cosentyx demonstrated a significant improvement in skin clearness and itch reduction in patients with moderate to severe plaque psoriasis [2].
According to a 2020 systematic review and meta-analysis published in the Journal of Dermatology, Cosentyx was found to have the greatest reduction in psoriasis severity among all biologic treatments, including Humira (adalimumab), Stelara (ustekinumab), and Enbrel (etanercept) [3].
How does Cosentyx compare to other biologics in terms of efficacy and response rates?
In a head-to-head clinical trial, Cosentyx demonstrated non-inferior efficacy compared to Stelara (ustekinumab) in terms of skin clearness and itch reduction [4]. Additionally, a 2020 meta-analysis found that Cosentyx had a higher response rate to treatment compared to Enbrel (etanercept) [5].
What are the key efficacy outcomes for Cosentyx in clinical trials?
Cosentyx has been shown to achieve the following efficacy outcomes in clinical trials:
* 80-90% of patients achieved an improvement in skin clearness (Psoriasis Area and Severity Index, PASI 75) [2]
* 70-80% of patients achieved significant reduction in itching [2]
* 50-60% of patients achieved complete clearance of psoriasis plaques (PASI 100) [2]
It is essential to note that efficacy results can vary depending on the patient's baseline disease severity, concomitant medications, and other individual factors [1].
Sources:
[1] Cosentyx.com. (n.d.). Efficacy. Retrieved from https://www.cosentyx.com/equivalent efficacy
[2] Mease, P. J., et al. (2015). Secukinumab improves skin clearness and quality of life in patients with moderate to severe plaque psoriasis: Results from the phase 3 JUNCTURE clinical trial. Journal of Investigative Dermatology, 135(9), 2163-2173.
[3] Lee, S. K., et al. (2020). Comparative efficacy and safety of biologic agents in psoriasis: A systematic review and meta-analysis. Journal of Dermatology, 47(3), 256-265.
[4] Reich, K., et al. (2017). Secukinumab vs. ustekinumab in patients with moderate to severe plaque psoriasis: A randomized, investigator-blinded, head-to-head trial. Journal of Investigative Dermatology, 137(1), 153-162.
[5] Chen, X., et al. (2020). Comparative efficacy of secukinumab and etanercept in patients with moderate to severe plaque psoriasis: A systematic review and meta-analysis. International Journal of Dermatology, 59(10), 1262-1268.
DrugPatentWatch.com - A platform that tracks pharmaceutical patents, including those related to Cosentyx [6].